Brief: Fresenius Enters Into Strategic Development Agreement With TQ Therapeutics
Jan 14 (Reuters) - FRESENIUS SE & CO KGAA FREG.DE: ENTERED INTO A STRATEGIC DEVELOPMENT AGREEMENT WITH TQ THERAPEUTICS TO SUPPORT SCALABLE AND EFFICIENT MANUFACTURING OF CELL AND GENE THERAPIES Further company coverage: FREG.DE (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 587785269;))
Recent news on Fresenius SE & Co. KGaA
See all newsFresenius lifts 2026 expectations after strong Q3 (updated)
Healthcare firm Fresenius Q3 revenue rises on Kabi growth; lifts outlook
Brief: Fresenius Sees FY26 EBIT Margin Above 11.5%
Brief: Fresenius SE Q3 Revenue EUR 5,803 Million
Fresenius signs biosimilars pipeline agreement with WuXi Biologics (updated)